U.S. Markets closed

GenVec, Inc. (GNVC)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
7.190.00 (0.00%)
At close: 3:58PM EDT
People also watch
CYCCHEBCTICCRISCVM
Full screen
Previous Close7.19
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume20,735
Market Cap16.35M
BetaN/A
PE Ratio (TTM)-1.94
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • PR Newswirelast month

    Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition

    With the addition of GenVec's AdenoVerse™ technology and accomplished team, Intrexon intends to create the next generation of adenoviral (AdV) delivery with significantly higher payload capacity that exceeds 30kb, as compared to current viral delivery methods ranging from 4.5kb – 9kb, through a scalable manufacturing platform utilizing helper-dependent adenovirus. Additionally Intrexon's RheoSwitch Therapeutic System® platform combined with GenVec's AdV-based technology is projected to accelerate its ability to develop cutting-edge gene therapies that regulate in vivo expression of one or several therapeutic effectors.  GenVec's selection of vector origins and serotypes as well as know-how in specifying cellular and tissue targets is expected to expedite the design and production of vectors that complement Intrexon's multigene programming and keen focus on safety with limited off-target effect.

  • GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
    Capital Cube2 months ago

    GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017

    Categories: Yahoo FinanceGet free summary analysis GenVec, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of GenVec, Inc. – Emergent BioSolutions Inc., Pfizer Inc., Novavax, Inc., Novartis AG Sponsored ADR, Merck & Co., Inc., Astrazeneca PLC Sponsored ADR and Johnson & Johnson (EBS-US, PFE-US, NVAX-US, ... Read more (Read more...)

  • PR Newswire3 months ago

    Act Now - Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of GenVec, Inc. - GNVC

    NEW YORK, April 23, 2017 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities class action firm headquartered at the Empire State Building ...